LIPOSOMAL

DRUG7 trials

Sponsors

Merck Sharp & Dohme LLC, Daiichi Sankyo Inc., Rita Fior, Champalimaud Clinical Centre, Rita Fior, AstraZeneca AB, Insmed Incorporated

Conditions

Advanced Platinum-resistant Epithelial Ovarian CancerHormone receptor positive breast cancerLocally recurrent inoperable or metastatic HR+/HER2- breast cancerLung infection Mycobacterial Lung InfectionOncology - Breast cancerOncology - Ovarian cancerPlatinum-resistanthigh-grade endometrioid OVC

Phase 2

A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

RecruitingCTIS2023-507914-28-00

Daiichi Sankyo Inc.high-grade endometrioid OVC, high-grade serous ovarian cancer (OVC), or fallopian tube cancer +2

Start: 2024-06-19Target: 293Updated: 2025-10-27

Phase 3

A Randomized, Open Label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) that are refractory to treatment

Active, not recruitingNL-OMON43943

Insmed IncorporatedLung infection Mycobacterial Lung Infection

Start: 2015-08-05Target: 8Updated: 2024-02-28

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)

Active, not recruitingCTIS2023-506752-24-00

Merck Sharp & Dohme LLCLocally recurrent inoperable or metastatic HR+/HER2- breast cancer, which has not been previously treated with cytotoxic chemotherapy in the noncurative setting

Start: 2021-08-05Target: 177Updated: 2025-09-03

An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

RecruitingCTIS2023-504918-29-00

Merck Sharp & Dohme LLCHormone receptor positive breast cancer

Start: 2024-08-22Target: 438Updated: 2026-01-26

An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)

RecruitingCTIS2025-520582-51-00

Merck Sharp & Dohme LLCHormone receptor positive breast cancer

Start: 2025-10-17Target: 211Updated: 2025-12-10

Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator’s Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

Not yet recruitingCTIS2025-520466-22-00

AstraZeneca ABAdvanced Platinum-resistant Epithelial Ovarian Cancer

Target: 46Updated: 2026-03-27

Phase 4

zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric randomized clinical study with intervention

RecruitingCTIS2023-509598-22-01

Rita Fior, Champalimaud Clinical Centre, Rita FiorOncology - Breast cancer, Oncology - Ovarian cancer

Start: 2025-05-13Target: 276Updated: 2025-10-21